RxDoctor Payments Data

Eugene Kaji, MD

Cardiovascular Disease · Fitchburg, WINPI 1093776874

Payments from drug & device makers

$2,053in general payments, 2019–2025

Across 95 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$407
  • Amgen$386
  • E.r. Squibb & Sons, L.L.C.$262
  • AstraZeneca$208
  • Bridgebio Pharma, Inc.$166
  • Novartis$159
  • plus $464 from 13 others

What the payments were for

  • Food & beverage$1,89592%
  • Education$1588%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,053 in reported general payments places this provider in the 60th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$7,269
Medicare patients
90
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban408$462,414
XareltoRivaroxaban187$222,087
FarxigaDapagliflozin Propanediol125$130,952
JardianceEmpagliflozin101$120,890
EntrestoSacubitril/Valsartan74$77,197
Repatha SureclickEvolocumab25$25,929
TrulicityDulaglutide18$17,271
Metoprolol Succinate734$11,091
Atorvastatin Calcium1,140$10,263
Ezetimibe506$8,715
Dofetilide12$4,314
Rosuvastatin Calcium433$4,151
Flecainide Acetate75$3,354
ClopidogrelClopidogrel Bisulfate283$3,292
Losartan Potassium347$2,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$462,414408 claims
Johnson & JohnsonXarelto$137$222,087187 claims
AstraZenecaFarxiga$208$130,952125 claims
Boehringer IngelheimJardiance$407$120,890101 claims
NovartisEntresto$159$77,19774 claims
Lilly USA, LLCTrulicity$39$17,27118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Fitchburg

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →